Fundraisings and IPOs

Date: 2014-03-14

Type of information: Series A financing round

Company: Inotrem (France)

Investors: Edmond de Rotschild Investment Partners (France) Sofinnova Partners (France) Biomed Invest (Switzerland) Inserm Transfert Initiative (France)

Amount: €18 million

Funding type: series A financing round

Planned used:

Created in 2013 by Prof. Sebastien Gibot, Dr. Marc Derive and Dr. Jean-Jacques Garaud, Inotrem is a French biotech company specializing in the discovery and development of novel treatments in the field of inflammatory pathologies with a focus on critical care. Based on the pioneering research work of Prof. Sebastien Gibot, professor of Critical Care Medicine at the University of Lorraine Medical School in Nancy; and Dr. Marc Derive, co-founder and CSO of Inotrem, the company has built a strong expertise around TREM-1, a pathway functioning as an amplifier of the immune response cycle. TREM-1 is particularly up-regulated in patients suffering from sepsis, an acute and severe infectious and inflammatory syndrome which can lead to multiple organ failure and death. Inotrem is developing an inhibitor of TREM-1 that has shown promising activity in a very broad series of sepsis animal models. The company is also working on a biomarker strategy to deliver a personalized healthcare solution with the aim to identify patients who would most likely benefit from the treatment.

This Series A round will support development of Inotrem’s lead product through late stage preclinical and early clinical trials in sepsis, plus the characterization of its therapeutic potential in other inflammatory diseases.




* On March 13, 2014, Inotrem, a French biotech company specialized in the control of immune reaction in acute inflammatory diseases, has announced the completion of its Series A financing round. With a total of €18 million, this round is the largest Series A round in Europe this year. The round was co-led by leading international life science venture capitalists Edmond de Rothschild Investment Partners and Sofinnova Partners. Switzerland-based Biomed Invest and the French seed investment firm InsermTransfert Initiative also participated in the round. 

Gilles Nobécourt of Edmond de Rothschild Investment Partners and Graziano Seghezzi of Sofinnova Partners have joined the Supervisory Board of Inotrem.

Therapeutic area: Inflammatory diseases

Is general: Yes